Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 85

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 7
Chunk 85
---
 continued listing requirements of The Nasdaq Capital Market could result in a de-listing of our Common Stock.

The
shares of our Common Stock are listed for trading on The Nasdaq Capital Market under the symbol “BIAF” and our Tradeable
Warrants are listed under the symbol “BIAFW.” On February 7, 2025, we received written notice from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that for the preceding 30 consecutive business days (December
23, 2024, through February 6, 2025), our Common Stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price
Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading
of our Common Stock, and the Common Stock will continue to trade on The Nasdaq Capital Market under the symbol “BIAF.” In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a compliance period of 180 calendar days, or until August 6, 2025, to regain
compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved without further action if the closing bid price of our Common
Stock is at or above $1.00 for a minimum of ten consecutive business days at any time during the 180-day compliance period, in which
case Nasdaq will notify us if it determines we are in compliance and the matter will be closed; however, Nasdaq may require the closing
bid price to equal or to exceed the $1.00 minimum bid price requirement for more than 10 consecutive business days before determining
that a company complies.

If,
however, we do not achieve compliance with the Minimum Bid Price Requirement by August 6, 2025, we may be eligible for additional time
to comply. In order to be eligible for such additional time, we will be required to meet the continued listing requirements for market
value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum
Bid Price Requirement, and must notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period.
We intend to actively monitor the bid price of our Common Stock and will consider available options to regain compliance with the Nasdaq
listing requirements.

If
we fail to satisfy the continued listing